

Fiscal Fourth Quarter 2015 Earnings

08/11/2015



MYRIAD®

Forward Looking Statements

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

Non-GAAP Financial Measures

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

	Fiscal Year 2016
GAAP diluted net income per share	\$1.45 - \$1.50
Acquisition – amortization of intangible assets	\$0.15
Non-GAAP diluted net income per share	\$1.60 - \$1.65

For additional information see on GAAP to non-GAAP reconciliation see:
<https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/>

4Q Results Provide Solid Finish to FY15

	Actual Results	Consensus Estimates	Difference
Revenue	\$189.9 M	\$187.8 M	+\$2.1 M
Adjusted EPS	\$0.41	\$0.41	\$0.00

GAAP EPS \$0.26

Significant FY15 Progress On Strategic Imperatives

Transition and Expand Hereditary Cancer Market

- **≈90%** Hereditary cancer market share*; **6%** 2-year revenue CAGR (FY15 vs. FY13)
- **72%** myRisk conversion from **30%** in Q1


Diversify the Portfolio

- **+63%** in Prolaris volume (and Final Medicare LCD)
- **+25%** in Vectra DA volume
- **+119%** in myPath Melanoma volume
- **+205%** in myPlan Lung Cancer volume
- **> 40%** increase in ovarian cancer revenue from BracAnalysis CDx in 2H15 vs. 1H15
- **2 RBM products** transferred to diagnostic development (BiPolar and Pancreatic)
- **140** publications/presentations


Increase International Contribution

- **+72%** increase in revenue (ex-German healthcare clinic)

Hereditary Cancer Shows Expected Sequential Growth



On Track To Complete Conversion By 1Q16




Excellent Strides in Doubling Oncology Market


Indication	Additional Patients /Year	Data	Guidelines	Coverage
All Endometrial	+47,000	✓	✓	In progress
Colon >5% risk	+28,000	✓	✓	In progress
Breast (<60 yrs) and all TNBC	+50,000	3 studies completed	FY16*	FY17*
All Pancreatic	+40,000	1 study completed	FY17*	FY17*

Represents about \$500M of incremental total addressable market per year


Ovarian Volumes Continue to Increase



Prolaris Volumes Growing Rapidly




Vectra DA Grows Sequentially




18% of Dermatopathologists Using myPath Melanoma

myPath Melanoma Physician Penetration



EndoPredict Placements Continue to Grow

**40 sites now
using
EndoPredict
on a global
basis**




***6 additional installations ROW**

Product Revenues up 6% Sequentially

Product	4Q15	3Q15	Sequential Growth
Hereditary Cancer Revenue	\$163.8	\$159.0	3%
Vectra DA Revenue	\$11.8	\$10.5	12%
Other Testing Revenue	\$3.3	\$3.5	(6%)
Total Molecular Diagnostic Revenue	\$178.8	\$173.0	3%
Pharmaceutical and Clinical Services	\$11.1	\$7.0	59%
Total Revenues	\$189.9	\$180.0	6%

Improving Gross Margins



FY16 Guidance

Revenue Guidance (Millions of Dollars)

Total Revenue

\$750 – \$770M

Earnings Guidance (Dollars)

GAAP EPS

\$1.45 – \$1.50

Adjusted Diluted EPS

\$1.60 – \$1.65

FY16 Guidance Assumptions (Revenue)

Downside Risks	Base Case for Guidance	Upside Potential
<ul style="list-style-type: none"> Hereditary cancer market losses > market growth 	<ul style="list-style-type: none"> Hereditary cancer revenue of \$638 to \$649 million 	<ul style="list-style-type: none"> Hereditary cancer market losses < market growth Impact from expanded payer coverage for colon and endometrial cancer
	<ul style="list-style-type: none"> Vectra DA revenue of \$50 to \$55 million 	<ul style="list-style-type: none"> Expanded private payer coverage
<ul style="list-style-type: none"> Medicare reimbursement starting later than Oct. 1, 2015 	<ul style="list-style-type: none"> Prolaris revenue of \$10 to \$12 million 	<ul style="list-style-type: none"> Private payer coverage Medicare reimbursement prior to Oct. 1, 2015 Expanded Medicare coverage
	<ul style="list-style-type: none"> Pharmaceutical and Clinical Services revenue of \$40M 	
	<ul style="list-style-type: none"> Other revenue of \$12 to \$14 million 	<ul style="list-style-type: none"> Reimbursement for EndoPredict, Tumor BRACAnalysis CDx, myPath Melanoma or myPlan Lung Cancer